Dr. Chorom Pak (Founder, President, and CEO) received her PhD in Molecular and Cellular Pharmacology from the UW-Madison and is a co-inventor of Lynx Biosciences’ platform technology. Prior to founding LynxBio, Dr. Pak served as Research and Clinical Development Lead at Cellectar Biosciences (NASDAQ:CLRB) where she lead R&D activities for the development of several therapeutic compounds. She has 10 years of experience in hematological malignancies with 5 patents in this field.
Prof. Edmond Young, PhD (CTO) is an Assistant Professor of Mechanical & Industrial Engineering at University of Toronto. He is a technology co-inventor and has authored over 30 publications in the fields of microfluidics and microscale technologies for cell biology studies. Dr. Young holds BASc and MASc degrees in Mechanical Engineering from the University of British Columbia and received a PhD in Mechanical and Biomedical Engineering at the University of Toronto.
Dr. Benjamin Titz (Director, Corporate Development) has over 12 years of experience in translational cancer research and the clinical development of cancer-targeted agents. He has previously served as Senior Manager of Corporate Development & Strategy at Cellectar Biosciences (NASDAQ:CLRB), where he acquired $2.3 MM in non-dilutive NCI grant funding. Ben holds a M.Eng. degree in Biomedical Engineering from THM Giessen (Germany) and MSc and PhD degrees in Medical Physics from the UW-Madison.
Kenneth Chng (Research Associate) has 5 years of experience in the development and validation and microfluidic devices and holds a BS degree in Microbiology and Immunology from the UW-Madison.
Prof. David Beebe, PhD (Director) is the Claude Bernard Professor of Biomedical Engineering and a John D. MacArthur Professor at the University of Wisconsin-Madison. He is the recipient of the IEEE EMBS Early Career Achievement Award, the Lab on a Chip, Royal Society of Chemistry/Corning, Pioneers of Miniaturization Prize, the Romnes Award and is a Fellow of the American Institute for Medical and Biological Engineering. In addition, Dr. Beebe was a founding Scientific Editor of Integrative Biology. David is a pioneer in the field of microfluidics and has published more than 225 archived journal articles. He is a co-inventor of Lynx Biosciences’ technology and has co-founded several biotechnology companies, including Salus Discovery, LLC, and Tasso, Inc.
Gregory Piefer, PhD (Director) is the founder and CEO of SHINE Medical Technologies and presently serves as its CEO. Dr. Piefer also served as the president of Phoenix Nuclear Labs, where he managed the development of high output particle sources. He formerly served as the Chief Technical Officer to Gillware, Inc., a leading data recovery and backup company. Dr. Piefer received Bachelor's degrees in physics, electrical, and computer engineering from UW Madison, and holds a Ph.D. in nuclear engineering.